Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Zeynep Eroglu

Showing results (91-100 of 116) with videos related to

Pageof 12
Sort By:
Therapeutic Advances in Medical Oncology|June 19, 2025
Proceedings of the seventh annual Women in Melanoma ConferenceYana G Najjar, Marlana Orloff, Tara C Mitchell, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2015
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsDouglas B Johnson, Alexander M Menzies, Lisa Zimmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous CancersKara M Schenk, Julie Stein Deutsch, Sunandana Chandra, et al.
Pigment Cell & Melanoma Research|February 16, 2019
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodiesInes Pires da Silva, Isabella C Glitza, Lauren E Haydu, et al.
Melanoma Research|March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.
Pigment Cell & Melanoma Research|February 4, 2019
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunitiesZeynep Eroglu, Sheri L Holmen, Qing Chen, et al.
Journal of the American Academy of Dermatology|October 15, 2023
Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-upAlexander J Stratigos, Aleksandar Sekulic, Ketty Peris, et al.
JAMA Oncology|September 23, 2018
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysisDaniel Y Wang, Joe-Elie Salem, Justine V Cohen, et al.
Cancer Discovery|November 12, 2021
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaKenneth F Grossmann, Megan Othus, Sapna P Patel, et al.
Frontiers in Immunology|December 3, 2025
Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphomaLilit Karapetyan, Joel Kuriakose, Matthew C Perez, et al.
Pageof 12

Showing results (91-100 of 116) with videos related to

Sort By:
Pageof 12
Therapeutic Advances in Medical Oncology|June 19, 2025
Proceedings of the seventh annual Women in Melanoma ConferenceYana G Najjar, Marlana Orloff, Tara C Mitchell, et al.
European Journal of Cancer (Oxford, England : 1990)|November 27, 2015
Acquired BRAF inhibitor resistance: A multicenter meta-analysis of the spectrum and frequencies, clinical behaviour, and phenotypic associations of resistance mechanismsDouglas B Johnson, Alexander M Menzies, Lisa Zimmer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2024
Nivolumab + Tacrolimus + Prednisone ± Ipilimumab for Kidney Transplant Recipients With Advanced Cutaneous CancersKara M Schenk, Julie Stein Deutsch, Sunandana Chandra, et al.
Pigment Cell & Melanoma Research|February 16, 2019
Incidence, features and management of radionecrosis in melanoma patients treated with cerebral radiotherapy and anti-PD-1 antibodiesInes Pires da Silva, Isabella C Glitza, Lauren E Haydu, et al.
Melanoma Research|March 4, 2021
Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922)Stergios J Moschos, Zeynep Eroglu, Nikhil I Khushalani, et al.
Pigment Cell & Melanoma Research|February 4, 2019
Melanoma central nervous system metastases: An update to approaches, challenges, and opportunitiesZeynep Eroglu, Sheri L Holmen, Qing Chen, et al.
Journal of the American Academy of Dermatology|October 15, 2023
Phase 2 open-label, multicenter, single-arm study of cemiplimab in patients with locally advanced basal cell carcinoma after hedgehog inhibitor therapy: Extended follow-upAlexander J Stratigos, Aleksandar Sekulic, Ketty Peris, et al.
JAMA Oncology|September 23, 2018
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysisDaniel Y Wang, Joe-Elie Salem, Justine V Cohen, et al.
Cancer Discovery|November 12, 2021
Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaKenneth F Grossmann, Megan Othus, Sapna P Patel, et al.
Frontiers in Immunology|December 3, 2025
Case Report: Durable response to tumor-infiltrating lymphocyte therapy in a patient with metastatic melanoma and chronic lymphocytic leukemia/small lymphocytic lymphomaLilit Karapetyan, Joel Kuriakose, Matthew C Perez, et al.
Pageof 12